Search
Results: 25
Familial Kidney Cancer
Maria I Carlo, A Ari Hakimi, Grant D Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W Marston Linehan, Eamonn R Maher, Maria J Merino, Kenneth Offit, Victor E Reuter, Brian Shuch, Jonathan A Coleman
Jun 28, 2019
CONTEXT: Hereditary cases account for about 5% of all cases of renal cell carcinoma (RCC). With advances in next-generation sequencing, several new hereditary syndromes have been described in the last few years. OBJECTIVE: To...
Birt-Hogg-Dubé syndrome Genetic counselling Hereditary cancer Hereditary leiomyomatosis renal cell carcinoma Hereditary papillary renal cell carcinoma kidney cancer renal cell carcinoma Tuberous sclerosis complex von Hippel-Lindau Disease Carcinoma Renal Cell Humans Leiomyomatosis Neoplastic Syndromes Hereditary Skin Neoplasms Syndrome Tuberous sclerosis Uterine Neoplasms von Hippel-Lindau Disease
Selenium and cancer risk
Shuai Yuan, Amy M Mason, Paul Carter, Mathew Vithayathil, Siddhartha Kar, Stephen Burgess, Susanna C Larsson
Jan 06, 2022
Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer.
Behnoush Abedi-Ardekani, Dariush Nasrollahzadeh, Lars Egevad, Rosamonde E Banks, Naveen Vasudev, Ivana Holcatova, Ctibor Povysil, Lenka Foretova, Vladimir Janout, Dana Mates, Viorel Jinga, Amelia Petrescu, Sasa Milosavljevic, Miodrag Ognjanovic, Simona Ognjanovic, Juris Viksna, Anne Y Warren, Mark Lathrop, Yasser Riazalhosseini, Christine Carreira, Estelle Chanudet, James McKay, Paul Brennan, Ghislaine Scélo
Jun 14, 2021
Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank.
Hannah Harrison, Lisa Pennells, Angela Wood, Sabrina H Rossi, Grant D Stewart, Simon J Griffin, Juliet A Usher-Smith
Sep 14, 2021
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma
Saeed Dabestani, Christian Beisland, Grant D Stewart, Karim Bensalah, Eirikur Gudmundsson, Thomas B Lam, William Gietzmann, Paimaun Zakikhani, Lorenzo Marconi, Sergio Fernandéz-Pello, Serenella Monagas, Samuel P Williams, Christian Torbrand, Thomas Powles, Erik Van Werkhoven, Richard Meijer, Alessandro Volpe, Michael Staehler, Börje Ljungberg, Axel Bex
May 30, 2018
BACKGROUND: Optimal follow-up (FU) strategy to detect potentially curable (PC) recurrences after treatment of localised clear cell renal cell carcinoma (ccRCC) is unclear. This study retrospectively analysed a large...
A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound.
Sabrina H Rossi, Tobias Klatte, Juliet A Usher-Smith, Kate Fife, Sarah J Welsh, Saeed Dabestani, Axel Bex, David Nicol, Paul Nathan, Grant D Stewart, Edward Cf Wilson
Sep 13, 2019
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro.
Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, Anne Y Warren, Tim Eisen, Sarah J Welsh, Antony CP Riddick, Fiach C O'Mahony, Arran Turnbull, Thomas Powles, Scotrrcc Collaborative, Antonio Reverter, David J Harrison, Grant D Stewart
Apr 03, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy
Robert J Ellis, Sharon J Del Vecchio, Kevin MJ Gallagher, Danielle N Aliano, Neil Barber, Damien M Bolton, Etienne TS Chew, Jeff S Coombes, Michael D Coory, Ian D Davis, James F Donaldson, Ross S Francis, Graham G Giles, Glenda C Gobe, Carmel M Hawley, David W Johnson, Alexander Laird, Steve Leung, Manar Malki, David JT Marco, Alan S McNeill, Rachel E Neale, Keng L Ng, Simon Phipps, Grant D Stewart, Victoria M White, Simon T Wood, Susan J Jordan
Apr 06, 2020
BACKGROUND: Clinically significant CKD following surgery for kidney cancer is associated with increased morbidity and mortality, but identifying patients at increased CKD risk remains difficult. Simple methods to stratify risk...
Nephrectomy chronic kidney disease Glomerular Filtration Rate kidney cancer renal cell carcinoma Risk stratification Aged Aged 80 and over Evidence-Based Medicine Female Glomerular Filtration Rate Humans Kidney Neoplasms Logistic Models Male Middle Aged Nephrectomy Postoperative Complications Renal Insufficiency Chronic Reproducibility of Results Risk Assessment Sensitivity and Specificity Severity of Illness Index
Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses.
Aurelien Dugourd, Christoph Kuppe, Marco Sciacovelli, Enio Gjerga, Attila Gabor, Kristina B Emdal, Vitor Vieira, Dorte B Bekker-Jensen, Jennifer Kranz, Eric MJ Bindels, Ana SH Costa, Abel Sousa, Pedro Beltrao, Miguel Rocha, Jesper V Olsen, Christian Frezza, Rafael Kramann, Julio Saez-Rodriguez
Mar 12, 2021
Multi-omics datasets can provide molecular insights beyond the sum of individual omics. Various tools have been recently developed to integrate such datasets, but there are limited strategies to systematically extract...
Public attitudes towards screening for kidney cancer
Laragh LW Harvey-Kelly, Hannah Harrison, Sabrina H Rossi, Simon J Griffin, Grant D Stewart, Juliet A Usher-Smith
Sep 17, 2020
BACKGROUND: Kidney cancer is often asymptomatic, leading to proposals for a screening programme. The views of the public towards introducing a new screening programme for kidney cancer are unknown. The aim of this study was to...
The current state of genetic risk models for the development of kidney cancer
Hannah Harrison, Nicole Li, Catherine L Saunders, Sabrina H Rossi, Joe Dennis, Simon J Griffin, Grant D Stewart, Juliet A Usher-Smith
May 09, 2022
European temporal trends in the use of lymph node dissection in patients with renal cancer
U Capitanio, GD Stewart, A Larcher, I Ouzaid, B Akdogan, M Roscigno, M Marszalek, P Dell'Oglio, M Salagierski, A Volpe, MC Mir, M Kriegmair, C Terrone, SD Brookman-May, F Montorsi, T Klatte, Kidney Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU)
Oct 04, 2017
BACKGROUND: The role of lymph node dissection (LND) in renal cell carcinoma (RCC) is still under debate. We aimed to assess the utilization rates of LND over time in Europe. METHODS: A multi-institutional database of 13,581 RCC...
Improving the Timely Detection of Bladder and Kidney Cancer in Primary Care.
Bladder and kidney cancer are the 10th and 7th most common cancers in the United Kingdom (UK). They present with symptoms that are typically investigated via the same diagnostic pathway. However, diagnosing these cancers can be...
Imaging activity possibly signalling missed diagnostic opportunities in bladder and kidney cancer
Yin Zhou, Gary A Abel, William Hamilton, Hardeep Singh, Fiona M Walter, Georgios Lyratzopoulos
Aug 25, 2020
INTRODUCTION: Sub-optimal use or interpretation of imaging investigations prior to diagnosis of certain cancers may be associated with less timely diagnosis, but pre-diagnostic imaging activity for urological cancer is unknown....
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart
Apr 08, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival
Saeed Dabestani, Christian Beisland, Grant D Stewart, Karim Bensalah, Eirikur Gudmundsson, Thomas B Lam, William Gietzmann, Paimaun Zakikhani, Lorenzo Marconi, Sergio Fernandéz-Pello, Serenella Monagas, Samuel Paul Williams, Christian Torbrand, Thomas Powles, Erik Van Werkhoven, Richard Meijer, Alessandro Volpe, Michael Staehler, Börje Ljungberg, Axel Bex
Dec 03, 2018
The optimal follow-up (FU) strategy for patients treated for localised renal cell carcinoma (RCC) remains unclear. Using the RECUR database, we studied imaging intensity utilised in contemporary FU to evaluate its association...
Early detection of kidney cancer using urinary proteins
Jordan G Flitcroft, Jeroen Verheyen, Tarun Vemulkar, Emma N Welbourne, Sabrina H Rossi, Sarah J Welsh, Russell P Cowburn, Grant D Stewart
Sep 27, 2021
Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
U Capitanio, GD Stewart, T Klatte, B Akdogan, M Roscigno, M Marszalek, P Dell'Oglio, E Zaffuto, O Rodriguez Faba, M Salagierski, J Lingard, M Carini, I Ouzaid, MC Mir, F Montorsi, LF Da Pozzo, C Stief, A Minervini, SD Brookman-May
May 11, 2017
Background
A non-negligible proportion of individuals diagnosed with cT1 renal cell carcinoma (RCC) are upstaged to pT3a at final pathology. Few data on oncological outcomes for these patients are available to determine whether...
Improving the Timely Detection of Bladder and Kidney Cancer in Primary Care
Abstract: Bladder and kidney cancer are the 10th and 7th most common cancers in the United Kingdom (UK). They present with symptoms that are typically investigated via the same diagnostic pathway. However, diagnosing these...
Prolonged Diagnostic Intervals as Marker of Missed Diagnostic Opportunities in Bladder and Kidney Cancer Patients with Alarm Features
Background: In England, patients who meet National Institute for Health and Care Excellence (NICE) guideline criteria for suspected cancer should receive a specialist assessment within 14 days. We examined how quickly bladder...
Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank
Hannah Harrison, Lisa Pennells, Angela Wood, Sabrina H. Rossi, Grant D. Stewart, Simon J. Griffin, Juliet A. Usher‐Smith
Oct 08, 2021
Original Article Original Articles kidney cancer public health modelling Risk models Risk stratification screening validation #kcsm #KidneyCancer #uroonc
Published by: BJU International
Prolonged Diagnostic Intervals as Marker of Missed Diagnostic Opportunities in Bladder and Kidney Cancer Patients with Alarm Features
Yin Zhou, Fiona M Walter, Hardeep Singh, William Hamilton, Gary A Abel, Georgios Lyratzopoulos
Jan 05, 2021
BACKGROUND: In England, patients who meet National Institute for Health and Care Excellence (NICE) guideline criteria for suspected cancer should receive a specialist assessment within 14 days. We examined how quickly bladder...
Management of the renal mass in a solitary kidney
The presence of tumour in a solitary kidney is an absolute indication for a nephron-sparing approach. Unique challenges exist in this patient population, and one must balance the desire for oncological control against predicted...